Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson's disease

• IDS score greater than 21

• Mini-Mental State Examination (MMSE) score greater than 15

Exclusion Criteria:

• Recent deep brain stimulation

• Currently participating in an antidepressant trial at a less than adequate dose and duration

• Severe depression or depression with suicide ideation

• History of liver toxicity

• Unstable medical disease or comorbid psychiatric disease